News & Analysis on Clinical Trial Services & Contract Research And Development
Clayton Dehn - Celerion
By Dan Stanton
- Last updated on
Finally this week, Celerion has appointed Clayton Dehn as Executive Director, Metabolic Diseases, as part of commitment to accelerating drug development through Applied Translational Medicine.
Dehn has 15 years of experience in drug development and has worked at two leading Contract Research Organizations (CROs), and also served as Director of Clinical Research and Development at a start-up biotech company.
“His comprehensive knowledge of specialized metabolic testing methods and hands-on operational experience will be a great asset to our organization and clients’ drug development programs,” said Phil Bach, VP Global Clinical Research.